178. Martínez Roig A, Camí J, LLorens Terol J, de la Torre R, Perich F. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics, 77, 912-915, 1986.

179. Martínez Jordà R. Estudio del fenotipo acetilador en el País Vasco. Actas 5a. Reunión de la Asociación Española de Farmacología. Tenerife, 1980.

180. Mazze RI, Woodruff RE, Heerdt E. Isoniazid-induced enflurane defluorination in humans. Anesthesiology, 57, 528, 1982.

181. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol, 34, 33-35, 1977.

182. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther, 38, 409-413, 1985.

183. McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. Br Med J, 2, 291-293, 1977.

184. McQueen EG. Pharmacological basis of adverse drug reactions. A Avery (dir) Drug Treatment, 2ª ed, pp 202-235. Adis Press, Sydney.

185. Mellström B, Swe J, Bertilsson L, Sjöqvist F. Amitriptyline metabolism: associaton with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther, 39, 369-371, 1986.

186. Mellström B, Bertilsson L, Swe J, Schulz HV, Sjöqvist F. E-and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther, 30, 189-193, 1981.

187. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH. Clonazepam acetylation in fast and slow

acetylators. Clin Pharmacol Ther, 30, 343-347, 1981.

188. Miller ME. Acetylator phenotype in bladder cancer. Lancet, 2, 1348, 1982.

189. Miller ME, Cosgriff JM. Acetylator phenotype in human bladder cancer. J Urol, 130, 65-66, 1983.

190. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow DJ, Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites Clin Pharmacol Ther, 18, 70-79, 1975.

191. Mitchell SC, Waring RH, Haley CS, Idle JR, Smith RI. Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man. Br J Clin Pharmacol, 18, 507-521, 1984.

192. Molin L, Larsson R, Karlsson E. Evaluation of the

sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand, 201, 217-222, 1977.

193. Moore MR. International review of drugs in acute porphyria - 1980. Int J Biochem, 12, 1089-1097, 1980.

194. Moore MR. McColl KEL, Goldberg A. Drugs and the acute porphyrias. Trends Pharmacol Sci, 2, 330-334, 1981.

195. Morris RJ, Freed CR, Kohler PF. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus. Arthr Rheum, 22, 777-780, 1979.

196. Motulski AG, Yoshida A, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase variants. Ann NY Acad Sci, 179, 636, 1971.

197. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin

between Japanese and caucasian populations. Clin Pharmacol Ther, 38, 402-408, 1985.

198. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med, 721, 809, 1964.

199. Oates NS, Shah RR, Idle JR, Smith RL. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther, 32, 81-89, 1982.

200. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther, 34, 827-834, 1983.

201. Oka M, Seppala O. Acetylation phenotype in rheumatoid arthritis. Scand J Rheumatol, 7, 29-30, 1978.

202. Olsen H, Morland J. Ethanol-induced increase in drug acetylation in man isolated rat liver cells. Br Med J, 2, 1260-1262, 1978.

203. Otton SV, Inaba T, Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci, 32, 795-800, 1983.

204. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci, 34, 73-80, 1984.

205. Osborne KH, De George FV. Genetic basis of morphological variation, an evaluation and aplication of the twin study method. Harvard University Press. Cambridge Mass, 1959.

206. Panayi GS, Huston G, Shah RR, Mitchell SC, Idle JR, Smith , Waring RH. Deficient sulphoxidation status and D-penicillamine toxicity. Lancet, 1, 414, 1983.

207. Paulsen O, Nilsson LG. Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol, 28, 311-315, 1985.

208. Paykel ES, West PS, Rowan PR, Parker RR. Influence of acetylator phenotype on antidepressant effects of phenelzine. Br J Psychiatry, 141, 243-248, 1982.

209. Peart GF, Boutagy J, Shenfield GN. Debrisoquin oxydation in an Australian population. Br J Clin Pharmac, 21, 465-471, 1986.

210. Penno MB, Vesell ES. Monogenic control of variations in antipyrine metabolite formation: new polymorphism of hepatic drug oxidation. J Clin Invest, 71, 1698-1709, 1983.

211. Perry Jr HM. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med, 54, 58-71, 1973.

212. Perry Jr HM, Tan EM, Cordoby S, Sahamato A. Relationship of acetyltransferase activity to antinuclear antibodies and toxic symptoms on hypertensive patients treated with hydralazine. J Laborat Clin Med, 76, 114-125, 1970.

213. Peters JH, Gordon GR, Murray JF. Metabolic disposition of dapsone in African leprosy patients. Leprosy Rev, 50, 7-19, 1979.

214. Peters JH, Murray JF, Gordon GR, Gelber RH. Dapsone in saliva and plasma of man. Pharmacology, 22, 162-171, 1981.

215. Petrakis NL, Wiesenfeld SL, Sams RJ, Collen MF, Cutler JL, Siegelaub AB. Prevalence of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med, 282, 767, 1970.

216. Philips PA, Rogers HJ, Millis RR, Rubens RD, Cartwight RA. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol, 23, 1701-1706, 1987.

217. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonism patients treated with antihistamine drugs. Lancet, 2, 386, 1987.

218. Poland A, Glover E. 2,3,7,8,-Tetrachlorodibenzo-p-dioxin: a potent inducer of delta-aminolevulinic acid synthetase. Science, 179, 476, 1973.

219. Pontiroli AE, De Pascua A, Bonisoli L, Pozza G. Ageing and acetylator phenotype as determined by administration of sulphadimidine. Eur J Clin Pharmacol, 28, 485-486, 1985.

220. Prankerd TAJ. The Red Cell. Thomas. Springfield, 1961.

221. Prankerd TAJ. Glucose-6-phosphate dehydrogenase deficiency. Proc R Soc Med, 57, 506-508, 1964.

222. Price Evans DA, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genetics, 20, 330-333, 1983.

223. Price Evans DA, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritchie J, Smith RL. The genetic control of sparteine and debrisoquine metabolism in man with new

methods of analysing bimodal distributions. J Med Genetics, 20, 321-329, 1983.

224. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genetics, 17, 102-105, 1980.

225. Price Evans DA, Manley KA, McKussick VA. Genetic control of isoniazid metabolism in man. Br Med J, 2, 485-491, 1960.

226. Price Evans DA, White TA. Human acetylation polymorphism. J Laborat Clin Med, 63, 394-403, 1964.

227. Raghupati Sarma G, Kailasam S, Nair NGK, Narayana ASL, Tripathy SP. Effect of prednisolone and rifampicin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicr Ag Chemother, 18, 661-666, 1980.

228. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ. Polymorphic ability to metabolize propranolol alter 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther, 36, 51-56, 1984.

229. Ramsay LE, Silas JH, Ollerenshaw JD, Tucker GT, Phillips FC, Freestone S. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension. Eur J Clin Pharmacol, 26, 39-42, 1984.

230. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy SP. Sulphadimidine acetylation test for classificaction of patients as slow or rapid inactivators of isoniazid. Br Med J, 3, 495-497, 1970.

231. Redondo FL, Miralles E, Bergón E, Ramos V. Acetilación hepática en la población española (carta). Gastroenterol Hepatol, 3, 107, 1980.

232. Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther, 28, 769-778, 1980.

233. Reidenberg MM. The clinical induction of systemic lupus erythematosus and lupus-like illnesses. Arthr Rheumat, 24, 1005-1009, 1981.

234. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther, 17, 722-730, 1975.

235. Reidenberg MM, Levy M, Drayer DE, Zylber-Katz E, Robbins WC. Acetylator phenotype in idiophatic systemic lupus erythematosus. Arthr Rheumat, 23, 569-573, 1980.

236. Reidenberg MM, Martin JH. The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Disp, 2, 71-73, 1974.

237. Ritchie JC, Sloan TP, Idle JR, Smith RL. Toxicological implications of polymorphic drug metabolism. In Environmental chemicals, enzyme function and human disease. CIBA Foundation Symposium, 76, 219-224, 1980.

238. Robson JM, Sullivan FM. Antituberculosis drugs. Pharmacol Rev, 15, 169-223, 1963.

239. Roden DN, Reele SB, Higgins SB, Mayol RF, Gammans RE, Oates JA, Woosley RL. Total suppression of ventricular arrhythmias by encainide. N Engl J Med, 302, 878-882, 1980.

240. Roden DN, Reele SB, Higgins SB, Smith R, Oates JA, Woosley RL. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in man. Am J Cardiol, 46, 463-468, 1980.

241. Rose S. The relationship of acetylation phenotype to treatment with MAOIs: A review. J Clin Psychopharmacol, 2, 161-164, 1982.

242. Rothfield NF, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies, a prospective study. Ann Intern Med, 88, 650-652, 1978.

243. Sanders GL, Rawlins MD. Phenelzine: acetylator status and clinical response. Br J Clin Pharmacol, 7, 451-452, 1979.

244. Saucedo R, Mayor B, Puche E. Estudio del fenotipo acetilador en Andalucía. Rev Clin Esp, 177, 75-77, 1985.

245. Schmid B, Bircher J, Preising R, Kupfe A. Polymorphic dextrometorfan metabolism: cosegregation of oxydative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther, 38, 618-624, 1985.

246. Schroeder P, Kligaard NA, Simonsen E. Significance of the acetylation phenotype and the therapeutic effect of procainamide. Eur J Clin Pharmacol, 15, 63-68, 1979.

247. Scott EM. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia. J Clin Invest, 39, 1176, 1960.

248. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes, 28, 41-51, 1979.

249. Shah RR, Oates NS, Idle JR, Smith RL. Beta-blockers and drug oxidation status. Lancet, 1, 508-509, 1982.

250. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J, 284, 295-299, 1982.

251. Sharp ME, Wallace S, Hindmarsh KW, Brown MA. Acetylator phenotype and serum levels of sulphapyridine in patients with inflammatory bowel disease. Eur J Clin Pharmacol, 21, 243-250, 1981.

252. Shepherd AMM, Lin M-S, McNay J, Ludden T, Musgrave G. Determinants of response to intravenous hydralazine in hypertension. Clin Pharmacol Ther, 30, 773-781, 1981.

253. Shepherd AMM, McNay JL, Ludden TM, Lin M-S, Musgrave GE. Plasma concentration and acetylator phenotype determine response total hydralazine. Hypertension, 3, 580-585, 1981.

254. Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol, 5, 27-34, 1978.

255. Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol, 14, 195-201, 1978.

256. Sjöqvist F, Borga O, Orme MLE. Fundamentals of clinical pharmacology. A Avery (dir), Drug

Treatment, 2ª ed, 32-33. ADIS Press, Sydney, 1980.

257. Sloan TP, Idle JR, Smith RL. Influence of D"/D' alleles regulating debrisoquine oxidation of phenytoin hydroxylation. Clin Pharmacol Ther, 29, 493-497, 1981.

258. Sloan TP, Lancaster R, Shah R, Idle JR, Smith RL. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol, 15, 443-450, 1983.

259. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J, 2, 655-657, 1978.

260. Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R. Genetically determined defects of oxidations at carbon centres of drugs. Lancet, 1, 943-944, 1978.

261. Sonnhag C, Karlsson E, Hed J. Procainamide-induced erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand, 206, 245-251, 1979.

262. Spina E, Steiner E, Ericsson, Sjöqvist F. Hydroxylation of demethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther, 41, 314-319, 1987.

263. Spina E, Bigersson C, von Bahr Ch, Ericsson, Steiner E, Sjöqvist F. Phenotyping consistency in hydroxylation of demethylimipramine and debrisoquine in healthy subjects in human liver microsomes. Clin Pharmacol Ther, 36, 677-682, 1984.

264. Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther, 38, 394-401, 1985.

265. Steiner E, Alván G, Garle M, Maguire JH, Lind M, Nilsson S-O, Tomson T, McClanahan JS, Sjöqvist F. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther, 42, 326-333, 1987.

266. Steiner E, Bertilsson L, Swe J, Berthing I, Sjöqvist F. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther, 44, 431-435, 1988.

267. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet, 2, 1082-1083, 1984.

268. Steventon G, Williams AC, Waring RH, Pall HS, Adams D. Xenobiotic metabolism in motoneuron disease. Lancet, 2, 644-647, 1988.

269. Strandberg I, Boman G, Hasster L, Sjöqvist F. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med

Scand, 200, 362-371, 1976.

270. Suhardjono D, Boutagy JS, Shenfield GM. Influence of blood glucose on acetylation status (Abstract). Clin Exp Pharmacol Physiol, Suppl 8, 64, 1984.

271. Surana MK, Mathur AK, Banerjee K, Agarwal TD. Correlation between acetylator phenotype and neuropathy in diabetes mellitus patients. J Ass Physicians India, 30, 437-439, 1982.

272. Syvlahti EKG, Lindberg R, Kallio J, de Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol, 22, 89-92, 1986.

273. Szórády I, Sánta A. Drug hydroxylator phenotype in Hungary. Eur J Clin Pharmacol, 32, 325, 1987.

274. Talseth T, Landmark KH. Polymorphic acetylation of sulphadimidine in normal and uraemic man. Eur J Clin

Pharmacol, 11, 33-36, 1977

275. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther, 42, 509-513, 1987.

276. Thom S, Farrow PR, Santoso B, Alberti KGMM, Rawlins MD. Effects of oral glucose in lime juice on isoniazid kinetics. Br J Clin Pharmacol, 11, 423P, 1981.

277. Timbrell JA, Harland SJ, Facchini V. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther, 28, 350-355, 1980.

278. Timbrell JA, Wright JM, Baillie TA. Monoacetyl-hydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther, 22, 602-608, 1977.

279. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J, 285, 261-262, 1982.

280. Vandenburg MJ, Wright P, Holmes J, Rogers HJ, Ahmad RA. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype. Br J Clin Pharmacol, 13, 747-750, 1982.

281. Vansant J, Woosley RL, John JT, Sergent JS. Normal distribution of acetylation phenotypes in systemic lupus erythematosus. Arthr Rheumat, 21, 192-195, 1978.

282. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther, 27, 96-103, 1980.

283. Vesell ES, Ng L, Passananti GT, Chase TN. Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet, 2, 370, 1971.

284. Vesell ES. Why individuals vary in their response to drugs, 1980. Trends Pharmacol Sci, 1, 349-351, 1980.

285. Vesell ES, Penno MB. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokin, 8, 378-409, 1983.

286. Voguel F, Motulski AG. Human genetics. Problems and approaches. Springer Verlag, Berlin, Heid NY, 1979.

287. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DR. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology, 33, 815-824, 1983.

288. Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL. Polymorphic sulphoxidation of S-carboxymethyl-L--cysteine in man. Biochem Pharmacol, 31, 3151-3154, 1982.

289. Wasserman RH, Taylor AN. Vitamin D3-induced calcium-binding protein in chick intestinal mucose. Science, 152, 791, 1966.

290. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokin, 94, 401-422, 1979.

291. Weber WW, Glowinski IB. Acetylation. A Jakoby (dir), Enzymatic basis for detoxication, 169-186. Academic Press, Nova York, 1980.

292. Weinshilboum RM. Biochemical genetics of catecholamines in humans. Mayo Clin Proc, 58, 319-330, 1983.

293. White TA, Price Evans DA. The acetylation of suphamethazine and sulphamethoxypyridazine by human subjects. Clin Pharmacol Ther, 9, 80-88, 1968.

294. Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH. A genetic study of familial hypophosphatemia and vitmamin D resistant rickets. Transact Ass Amer Physicians, 70, 234, 1957.

295. Wiholm BE. El sistema sueco de detección y

cuantificación de reacciones adversas a medicamentos. A Laporte J i Laporte JR (dirs), Avances en terapéutica, vol 15, 44-63. Salvat. Barcelona, 1988.

296. Wolf H, Lower Jr GM, Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol, 14, 161-165, 1980.

297. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther, 26, 584-591, 1979.

298. Woolhouse NM, Atu-Taylor LC. Influence of double genetic polymorphism on response to sulfamethazine. Clin Pharmacol Ther, 31, 377-383, 1982.

299. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the

rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med, 298, 1157-1159, 1978.

300. Woosley R, Roden DM, Dai G, Wang T, Altenberg D, Oates J, Wilkinson G. Co-inheritance of the polymorphic metabolism of encainide and debrisoquine. Clin Pharmacol Ther, 39, 282-287, 1986.

301. Woosley RL, Roden DM, Duff HG, Carey BL, Wood AJJ, Wilkinson GR. Coinheritance of deficient oxidative metabolism of encainide and debrisoquine. Clin Res, 29, 501A, 1981.

302. Ylitalo P, Ruosteenoja R, Leskinen O, Mets-Ketel T. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. Eur J Clin Pharmacol, 25, 791-795, 1983.

303. Yoshida A. Hemolytic anemia and G6PD deficiency. Science, 179, 532, 1973.

304. Young JR. Acetylator status and liver function profile changes in labyrinthine ischaemia patients with thymoxamine. Int J Med Res, 8, 356-357, 1980.

305. Zacest R, Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther, 13, 420-425, 1972.

306. Zidek Z, Janku I. Estrogen dependent differences in the rat. Pharmacology, 19, 209-214, 1979.

307. Zinkham WH, Childs B. Effect of vitamin K and naphthalene metabolites on glutathione metabolism of erythrocytes from normal newborns and patients with naphthalene hemolytic anemia. Am J Dis Child, 94, 420, 1957.